evolution of prp and stem cells
play

Evolution of PRP and stem cells Lisa A. Fortier, DVM, PhD, DACVS - PowerPoint PPT Presentation

Cornell University College of Veterinary Medicine Evolution of PRP and stem cells Lisa A. Fortier, DVM, PhD, DACVS James Law Professor of Surgery laf4@cornell.edu Disclosures: Arthrex Consultant, VRN Consultant, Scientific Board Kensey Nash


  1. Cornell University College of Veterinary Medicine Evolution of PRP and stem cells Lisa A. Fortier, DVM, PhD, DACVS James Law Professor of Surgery laf4@cornell.edu Disclosures: Arthrex Consultant, VRN Consultant, Scientific Board Kensey Nash

  2. Disclosures • Consultant: Arthrex, Veterinary Recommended Nutraceuticals, TissueGen • Royalties: Arthrex • Scientific Board: Kensey Nash

  3. Goal of biologics • Repair, restore, regenerate tissue • Reduce pain, restore function Evidence: OA - strong Tendon (upper > lower) - modest Muscle - weak

  4. What is PRP? • No consensus on definition • Growth factors released from platelet α -granules (TGF, PDGF, VEGF, BMPs) • Some is good −> more is better

  5. WBC - degrade normal matrix Platelets - more is not better Platelets WBC ↑COL1A1:COL3A1 ↑MMP -3 ↑COMP ↑MMP -13 9 IL-1B (pg/mL) R² = 0.6459 8 ↓MMP -3 ↓COL1A1:COL3A1 7 6 ↓MMP -13 ↓COMP 5 4 McCarrel , Fortier JOR, 2010 Blo… 3 2 1 0 Platelet: Platelets 0 10 20 30 (10 3 /µl) WBC neutrophils… ratio 2000:1 500 2000:1 1500 200 2000:1 August 2011 AJSM NA NA McCarrell, Fortier, Minas. JBJS 2013 Yoshida, Murray JOR 2013 Boswell, Fortier, Minas. AJSM 2013

  6. More is not better • Synoviocytes – Assirelli, Knee Surg Sports Traum Arthosc 2014 • Tendon – Cross, AJSM 2015 • ACL – Yoshida, JOR 2014. JOR 2011 • Meniscus, cartilage – Kisiday, Cartilage 2012 • Pain/function – Cole, ICRS 2015

  7. PRP and OA pain TNF- α in “joint fluid” 12 A 10 TNF- α ( pg/ml) B 8 B 6 4 2 0 Control ACP HA HA in synoviocytes MMP 13-in synoviocytes 1.4 0 log HAS-2 Fold Change over A log MMP-13 Fold Change over 1.2 Control ACP HA -0.2 A 1 -0.4 Control 0.8 A Control 0.6 -0.6 0.4 B -0.8 0.2 B -1 0 Control ACP HA B -1.2 Sundman, AJSM 2014 Duif C. Arch Orthop Thaum Surg 2015

  8. Group 2: =3 Group 1: <3 A I B A K C D J E L M F A H G N O Cross, AJSM 2015 Quantitative strain elastography B

  9. PRP and BMC recruit MSCs PDGF PRP Holmes PLOS ONE 2017

  10. Is BMC just PRP with a few MSC? BMC PRP PRP in femoral condyle BMC in femoral condyle Cassano KSSTA 2016

  11. IL-1ra / Orthokine / IRAP BMA BMC-A BMC-B WB PRP MSC + +++ ++ - - TGF- β1, PDGF + +++ ++ + +++ Il- 1β, IL -8 + ++ ++ - - Reported IRAP concentrations

  12. Fallen stem cell paradigms Fortier, Tuan. Small Animal Surgery, 2011 Bunnell. Stem Cell Res and Therapy, 2010.

  13. MSC licensing / activation Cassano, Vet Imm 2017 Cassano, SSRT, 2018 K English, Imm and Cell Bio, 2013 Fortier, Sports Health, 2017

  14. MSC in PTOA

  15. OC histology – cartilage and subchondral bone are protected - impact + impact - impact + impact control control MSC MSC

  16. What we now know • MSCs mitigate PTOA • They are not immunopriveledged • They don’t polarize • Activation makes them super stem cells – Regardless of source Schnabel Goodalde Hill Cassano

  17. Rehabilitation basics Pressage 50 µm 50 µm Injured

  18. Acknowledgements

Recommend


More recommend